
## Atul Bhardwaj

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/691952/publications.pdf Version: 2024-02-01



Δτιίι Βηνδυννί

#	Article	IF	CITATIONS
1	Fluorine-18 Labelled Radioligands for PET Imaging of Cyclooxygenase-2. Molecules, 2022, 27, 3722.	1.7	1
2	In Cellulo Generation of Fluorescent Probes for Live ell Imaging of Cylooxygenaseâ€2. Chemistry - A European Journal, 2021, 27, 3326-3337.	1.7	4
3	Development of Fluorescence Imaging Probes for Labeling COX-1 in Live Ovarian Cancer Cells. ACS Medicinal Chemistry Letters, 2021, 12, 798-804.	1.3	5
4	Synthesis, binding affinity analysis, and 18Fâ€radiosynthesis of small molecular weight HIFâ€1α binding compounds ChemMedChem, 2021, , .	1.6	0
5	Synthesis and Preclinical Evaluation of [ <sup>18</sup> F]SiFA-PSMA Inhibitors in a Prostate Cancer Model. Journal of Medicinal Chemistry, 2021, 64, 15671-15689.	2.9	6
6	Design, Synthesis, and Evaluation of a Luminescent Cholesterol Mimic. Journal of Organic Chemistry, 2021, 86, 1612-1621.	1.7	2
7	Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant <i>Enterococcus</i> . Journal of Medicinal Chemistry, 2020, 63, 9540-9562.	2.9	57
8	The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor. Synthetic Communications, 2019, 49, 1436-1443.	1.1	4
9	Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 420-423.	1.0	16
10	Glutathione <i>S</i> -Transferase π-Activatable <i>O</i> <sup>2</sup> -(Sulfonylethyl Derived) Diazeniumdiolates Potently Suppress Melanoma in Vitro and in Vivo. Journal of Medicinal Chemistry, 2018, 61, 1833-1844.	2.9	17
11	In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nature Communications, 2017, 8, 1.	5.8	10,736
12	Pyrimidine-based fluorescent COX-2 inhibitors: synthesis and biological evaluation. Organic and Biomolecular Chemistry, 2016, 14, 7250-7257.	1.5	11
13	Design and synthesis of [ 125 I]Pyricoxib: A novel 125 I-labeled cyclooxygenase-2 (COX-2) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1516-1520.	1.0	7
14	NSAIDs do not require the presence of a carboxylic acid to exert their anti-inflammatory effect – why do we keep using it?. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1018-1028.	2.5	17
15	Design, Synthesis, and Evaluation of an <sup>18</sup> Fâ€Labeled Radiotracer Based on Celecoxib–NBD for Positron Emission Tomography (PET) Imaging of Cyclooxygenaseâ€2 (COXâ€2). ChemMedChem, 2015, 10, 1635-1640 Combined Measurement of the Higgs Boson Mass in <mml:math< td=""><td>1.6</td><td>27</td></mml:math<>	1.6	27
16	xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"> <mml:mi>p</mml:mi> cmml:mi>pCollisions at <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline"&gt;<mml:msqrt><mml:mi>s</mml:mi></mml:msqrt><mml:mo>=</mml:mo>&lt;<mml:mn>7<td>2.9 &gt; <td>1,062</td></td></mml:mn></mml:math 	2.9 > <td>1,062</td>	1,062
17	8ÅTeV with the ATLAS and CMS Experiments. Physical Review Letters, 2015, 114, 191803. Fluorophoreâ€Labeled Cyclooxygenaseâ€2 Inhibitors for the Imaging of Cyclooxygenaseâ€2 Overexpression in Cancer: Synthesis and Biological Studies. ChemMedChem, 2014, 9, 109-116.	1.6	36
18	Do nitric oxide-releasing drugs offer a potentially new paradigm for the management of	0.6	3

<sup>18</sup> cardiovascular risks in diabetes?. Expert Review of Cardiovascular Therapy, 2014, 12, 533-536.

2

Atul Bhardwaj

#	Article	IF	CITATIONS
19	Hybrid fluorescent conjugates of COX-2 inhibitors: Search for a COX-2 isozyme imaging cancer biomarker. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 163-168.	1.0	37
20	A diazen-1-ium-1,2-diolate analog of 7-azabenzobicyclo[2.2.1]heptane: Synthesis, nitric oxide and nitroxyl release, in vitro hemodynamic, and anti-hypertensive studies. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2769-2774.	1.0	2
21	Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?. Future Medicinal Chemistry, 2013, 5, 381-383.	1.1	4
22	1,4-Diaryl-substituted triazoles as cyclooxygenase-2 inhibitors: Synthesis, biological evaluation and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2013, 21, 4288-4295.	1.4	14
23	Synthesis and Biological Investigations of Nitric Oxide Releasing Nateglinide and Meglitinide Type II Antidiabetic Prodrugs: In-Vivo Antihyperglycemic Activities and Blood Pressure Lowering Studies. Journal of Medicinal Chemistry, 2012, 55, 7883-7891.	2.9	33
24	<i>O</i> <sup>2</sup> -Sulfonylethyl Protected Isopropylamine Diazen-1-ium-1,2-diolates as Nitroxyl (HNO) Donors: Synthesis, β-Elimination Fragmentation, HNO Release, Positive Inotropic Properties, and Blood Pressure Lowering Studies. Journal of Medicinal Chemistry, 2012, 55, 10262-10271.	2.9	19
25	Cardiovascular Properties of a Nitric Oxide Releasing Rofecoxib Analogue: Beneficial Antiâ€hypertensive Activity and Enhanced Recovery in an Ischemic Reperfusion Injury Model. ChemMedChem, 2012, 7, 1365-1368.	1.6	17
26	N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: Synthesis and biological evaluation. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2154-2159.	1.0	41
27	Rofecoxib Analogues Possessing a Nitric Oxide Donor Sulfohydroxamic Acid (SO <sub>2</sub> NHOH) Cyclooxygenaseâ€2 Pharmacophore: Synthesis, Molecular Modeling, and Biological Evaluation as Antiâ€inflammatory Agents. ChemMedChem, 2012, 7, 62-67.	1.6	24
28	Aspirin Analogues as Dual Cyclooxygenaseâ€2/5â€Lipoxygenase Inhibitors: Synthesis, Nitric Oxide Release, Molecular Modeling, and Biological Evaluation as Antiâ€Inflammatory Agents. ChemMedChem, 2012, 7, 144-150.	1.6	20
29	Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6074-6080.	1.0	11
30	Synthesis of highly functionalized barbituric acids and study of their interactions with p-glycoprotein and Mg2+ – Potential candidates for multi drug resistance modulation. European Journal of Medicinal Chemistry, 2010, 45, 1256-1262.	2.6	18
31	Mono-, Di-, and Triaryl Substituted Tetrahydropyrans as Cyclooxygenase-2 and Tumor Growth Inhibitors. Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2010, 53, 3707-3717.	2.9	45
32	Design, synthesis and evaluation of tetrahydropyran based COX-1/-2 inhibitors. European Journal of Medicinal Chemistry, 2009, 44, 1278-1287.	2.6	18
33	1-Toluene-sulfonyl-3-[(3′-hydroxy-5′-substituted)-γ-butyrolactone]-indoles: Synthesis, COX-2 inhibition and anti-cancer activities. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 85-89.	1.0	24
34	Mechanism of Action of Key Enzymes Associated with Cancer Propagation and their Inhibition by Various Chemotherapeutic Agents. Mini-Reviews in Medicinal Chemistry, 2008, 8, 388-398.	1.1	18